Publications

2023

Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer. Nat Comm. In press!

Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314.Eur Urol Oncol. 2023 Apr 20:S2588-9311(23)00074-3.

Circulating and urinary tumour DNA in urothelial carcinoma – upper tract, lower tract and metastatic disease. Nat Rev Urol. 2023 Mar 28. doi: 10.1038/s41585-023-00725-2.

2022

Role of Chromatin Modifying Complexes and Therapeutic Opportunities in Bladder Cancer. Bladder Cancer. 2022 Jun 3;8(2):101-112. doi: 10.3233/BLC-211609

Biodegradable nanoparticles induce cGAS/STING-dependent reprogramming of myeloid cells to promote tumor immunotherapy. Front Immunol. 2022 Aug 18;13:887649. doi: 10.3389/fimmu.2022.887649.

First-in-human Intravesical Delivery of Pembrolizumab Identifies Immune Activation in Bladder Cancer Unresponsive to Bacillus Calmette-Guérin. Eur Urol. 2022 Dec;82(6):602-610. doi: 10.1016/j.eururo.2022.08.004

Immune activation is essential for the antitumor activity of EZH2 inhibition in urothelial carcinoma. Sci Adv 2022 Oct 7;8(40):eabo8043. doi: 10.1126/sciadv.abo8043

2021

An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. Nat Comm. 2021 Apr 16;12(1):230  doi: 10.1038/s41467-021-22465-w.

γδ T Cells Support Antigen-Specific αβ T cell-Mediated Antitumor Responses during BCG Treatment for Bladder Cancer. Cancer Immunol Res 2021 Dec;9(12):1491-1503. doi: 10.1158/2326-6066.CIR-21-0285. Epub 2021 Oct 4

Subtype-associated epigenomic landscape and 3D genome structure in bladder cancer.Iyyanki T, Zhang B, Wang Q, Hou Y, Jin Q, Xu J, Yang H, Liu T, Wang X, Song F, Luan Y, Yamashita H, Chien R, Lyu H, Zhang L, Wang L, Warrick J, Raman JD, Meeks JJ, DeGraff DJ, Yue F.Genome Biol. 2021 Apr 15;22(1):105. doi: 10.1186/s13059-021-02325-y.

MutSignatures: an R package for extraction and analysis of cancer mutational signatures. Fantini D, Vidimar V, Yu Y, Condello S, Meeks JJ.Sci Rep. 2020 Oct 26;10(1):18217. doi: 10.1038/s41598-020-75062-0.

Identification of Differential Tumor Subtypes of T1 Bladder Cancer. Robertson AG, Groeneveld CS, Jordan B, Lin X, McLaughlin KA, Das A, Fall LA, Fantini D, Taxter TJ, Mogil LS, Lindskrog SV, Dyrskjøt L, McConkey DJ, Svatek RS, de Reyniès A, Castro MAA, Meeks JJ.Eur Urol. 2020 Oct;78(4):533-537. doi: 10.1016/j.eururo.2020.06.048. Epub 2020 Jul 17.

Surgeon Scorecards Improve Muscle Sampling on Transurethral Resection of Bladder Tumor and Recurrence Outcomes in Patients with Nonmuscle Invasive Bladder Cancer. Das A, Cohen JE, Ko OS, Jordan BJ, Glaser AP, Auffenberg GB, Meeks JJ.J Urol. 2021 Mar;205(3):693-700. doi: 10.1097/JU.0000000000001372. Epub 2020 Oct 6.

A compilation of all publications can be found on PubMed or Google Scholar.

---